Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study.
Paediatr Drugs
January 2025
Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Background: The effectiveness of crisaborole for proactive treatment of atopic dermatitis (AD) is not well established.
Objectives: This study aims to investigate the efficacy and safety of a proactive treatment strategy with 2% crisaborole ointment for managing mild-to-moderate AD in children.
Patients And Methods: In this 16-week randomized-controlled trial, children aged 2-17 years with mild-to-moderate AD were enrolled.
Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.
Paediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFCorrelates of length of stay in a short-term inpatient residential addiction treatment facility.
Alcohol Clin Exp Res (Hoboken)
January 2025
Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, New York, USA.
Background: There is a gap in the extant literature regarding length of stay (LOS) in short-term inpatient addiction treatment facilities. Furthermore, there is a lack in focus on treatment factors which may be better indicators for positive patient outcomes than demographic profiles. The current study sought to examine modifiable correlates of LOS within a short-term inpatient residential facility to extend LOS and improve patient outcomes.
View Article and Find Full Text PDF[WHO classification of melanocytic tumours].
Dermatologie (Heidelb)
January 2025
MVZ Dermatohistopathologie Heidelberg, Mönchhofstr. 52, 69120, Heidelberg, Deutschland.
Background: The update of the World Health Organisation (WHO) classification of skin tumours has led to new aspects in the classification of melanocytic tumours.
Objectives: Presentation of the classification of melanocytic tumours in light of current clinical, histological and genetic data.
Materials And Methods: Review of the classification of melanocytic neoplasms in the fifth edition of the WHO classification of skin tumours, taking into account current disease concepts.
Advanced measurement methods for high-power gallium nitride high electron mobility transistors.
Rev Sci Instrum
January 2025
Key Laboratory of Advanced Science and Technology on High Power Microwave, Northwest Institute of Nuclear Technology, Xi'an 710024, China.
The testing and modeling of semiconductor devices are the foundation of circuit design. The issue of high-power device testing urgently needs to be solved as the power level of the devices under test (DUTs) increases. This work proposes advanced measurement methods based on three aspects of "measuring capability, security, and stability" with a focus on the features of high output power, easy self-oscillation in mismatch tests, and safety risk in the measurement system of high-power transistors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!